SIGA (SIGA) Q2 2026 Earnings Call Transcript

SIGA reported Q2’26 total revenue of $41.0M, down from $81.1M year over year, driven by variable delivery timing. Operating income fell to $13.9M (from $45.7M) and net income declined to $12.5M (from $35.5M), with diluted EPS dropping to $0.17 from $0.49. The company completed the final IV TPOXX shipment under the 19C SNS order and is negotiating a successor U.S. multiyear contract, but progress has been slower due to HHS transition/priority shifts; it targets an FDA submission for the PEP program in 1H’27.

Analysis

SIGA is moving from a contract-backed cash flow story to a gap-period story, and that transition usually earns a lower multiple before it earns a new one. The balance sheet keeps this from being a solvency problem, but it does not solve the core issue: revenue visibility drops sharply once the last U.S. order is behind it, so the stock should trade more like an event-driven option than a steady compounder until a successor award is visible.

The near-term beneficiaries are not obvious end-market peers so much as the intermediaries that can scale regional commercialization without carrying the same political baggage; Hikma’s role is economically attractive because it gets distribution economics with limited capital intensity. The bigger competitive risk is opportunity cost: if U.S. procurement remains stalled, biodefense dollars can migrate toward alternative countermeasures or broader preparedness budgets, which would pressure SIGA’s bargaining power even if the end demand for stockpiles stays intact.

The key catalyst window is the next 1-3 months on U.S. contract timing and 6-18 months on whether the PEP and pediatric programs become real labeling or merely regulatory placeholders. Consensus may be underestimating how little the current international pipeline can replace in the near term; a March 2027 delivery target is too distant to de-risk the next several quarters. What would falsify the bearish setup is a credible multiyear U.S. award or a materially larger international order that demonstrates repeatability rather than one-off stocking.

Key Decisions for Investors

• Avoid initiating fresh long exposure in SIGA over the next 4-8 weeks; the setup is still a revenue-gap transition, not a reacceleration story.
• If SIGA rallies on contract optimism, buy 1-3 month put spreads 5-10% below spot to express the view that the market is overpricing near-term procurement timing; risk/reward improves if no award lands before the next quarter.
• For existing holders, trim to a core position and treat the name as a special-situation optionality trade only until a new U.S. award is announced; reassess on any signed multiyear contract.
• Set a hard alert on two events: a new U.S. contract announcement or a larger-than-usual international order. Either event should force a rapid thesis review because it would invalidate the current low-visibility revenue bridge.